David Liew, a renowned rheumatologist from Melbourne, joins an expert panel to discuss groundbreaking findings from the ACR Annual Meeting. They explore the effectiveness of Upadacitinib for treating giant cell arteritis and the complexities surrounding patient enrollment for trials. The conversation shifts to the skepticism around methotrexate for polymyalgia rheumatica and the potential of JAK inhibitors in myositis. Safety concerns regarding these therapies, particularly in cardiovascular health, underscore the importance of ongoing research.

Rheumatologists Eric Dein from Atlantic Health, Jiha Lee from the University of Michigan, and Jeffrey Spark from Harvard Medical School dive into crucial topics surrounding rheumatoid arthritis. They discuss the importance of statin prescription amidst cardiovascular risks and the challenges of steroid use, particularly for elderly patients. Innovations in remote monitoring with smartphone technology and AI are highlighted, alongside a study aimed at improving fertility for women with RA, showcasing advancements in tailored treatment strategies.

Join Artie Kavanaugh, a rheumatologist from UC San Diego, and Quillen Connelly from Galway Clinic, as they delve into the intricate realm of psoriatic arthritis. They discuss the rising placebo response rates tied to socioeconomic factors and the urgent need for gender-specific research in treatment. Artie breaks down the potential of combination therapies, while Quillen shares insights on the durable effectiveness of bimikizumab. Together, they illuminate the latest advancements in diagnosis and treatment, providing a comprehensive overview for clinicians.

Dive into the highlights from the ACR 2024 meeting in Washington, DC, featuring exciting advancements in rheumatology treatments. Discover innovative therapies for conditions like rheumatoid arthritis and lupus, as well as the environmental impact of adalimumab and its biosimilars. Learn about the promising effects of GLP-1 drugs and groundbreaking AI-driven ultrasound technology in diagnostics. The discussion wraps up with upcoming events for networking and collaboration in the field. Tune in for a mix of insights and practical updates!

In this engaging discussion, Lihi Eder, an expert in psoriatic arthritis from the University of Toronto, Sheila Reyes, a Filipino rheumatologist, and Adela Castro, a clinical assistant professor in Memphis, tackle the latest breakthroughs in spondyloarthritis. They dive into challenges in diagnosing axial spondyloarthritis and the importance of updated classification criteria. Gender differences in treatment responses and personalized approaches are highlighted, along with insights on treatment failures and strategic switches between biologic therapies. Tune in for essential insights!

A New ACR Cancer Survival in RA "Changing Mindsets about Methotrexate Side Effects" Control RA, Build Stronger Bones Cumulative Steroid Use and Cardiovascular Events Disease Activity in RA-ILD Do TNFis and JAKis Prevent Cancer!? Estimating Inflammation, Damage and Patient Distress Finding the Right Combination Therapy in RA Implantable Vagus Nerve Stimulator for RA Is Frequent Lab Monitoring Necessary? Long Term Follow up from APIPPRA Metabolic Dysregulation and RA Interstitial Lung Disease Native Americans with RA Die Young Paraoxonase-1: Possible Biomarker for Progression to RA Pred Softly: Steroids Predicting Flares in Rheumatoid Arthritis RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA Treatment Adherence: Is decision making really shared? RA: One JAK to Rule Them All? Sonelokimab in PsA: Phase 2 Data Treat-to-Target Improves Fertility in Women with RA Treatment Considerations for RA-ILD Treatment Strategies in RA Use of AI in Hand Ultrasound Scoring Vaccine Responses:The DMARD Counts What's New in Relapsing Polychondritis? What's The State of Biosimilars?

In this engaging discussion, Philip Meese, a seasoned rheumatologist, delves into the latest advancements in IL-17 treatments for psoriatic arthritis and axial spondyloarthritis. He shares intriguing real-world data on the efficacy and safety of Bimekizumab, highlighting significant improvements in pain and fatigue. The conversation also explores treatment strategies comparing TNF and IL-17 inhibitors, revealing insights from a large patient study. Additionally, Meese discusses the long-term safety profile of Bimekizumab and other emerging therapies, emphasizing personalized patient care.

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Andrea Fava is an expert in lupus nephritis diagnostics, while Chris Winkup is a consultant rheumatologist focused on CAR-T therapy. They dive into the challenges of diagnosing lupus nephritis with new non-invasive biomarkers. The discussion highlights the impact of positive ANA patterns on liver disease, and the advancements in CAR-T therapy for targeting harmful B-cells. They also touch upon vaccination responses and the complexities surrounding neuropsychiatric lupus, emphasizing the need for enhanced patient-clinician communication.

Adela Castro presents CLASSIC study results, exploring the ASAS criteria for axSpA. Anthony Chan discusses the BASTI score and defines difficult-to-manage axSpA. Marina Magre highlights key abstracts from the ACR meeting. Dr. Sheila Reyes explains how machine learning predicts flares and the impact of gender on axSpA. Professor Walter Maximowicz shares the 3-4-5 rule for interpreting positive MRI findings, enhancing understanding of spondyloarthritis diagnostics. Together, they showcase significant advancements in research and treatment strategies.